查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529839

CRO 體內腫瘤學市場規模、佔有率和趨勢分析報告：按適應症、地區、細分市場預測，2024-2030 年

Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report By Indication (Blood Cancer, Solid Tumor, Others), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

體內腫瘤學市場成長與 CRO 趨勢：

Grand View Research, Inc. 的最新報告顯示，到 2030 年，CRO 體內腫瘤學的全球市場規模預計將達到 23.7 億美元。

預計該市場在預測期內將以 8.58% 的複合年成長率成長。研發活動外包的增加、對先進藥物的高需求以及 CRO 對國際標準的採用是推動市場成長的主要因素。

此外，專利到期導致的競爭加劇、學名藥的快速成長以及生物相似藥的推出等壓力正促使製藥公司尋求 CRO 援助。因此，可以預測，基於腫瘤的體內CRO產業在預測期內可能會出現良好的成長。

用於招募和溝通市場參與企業的行動創新、基於網路的生命科學實驗室以及用於執行例行測試的機器人實驗室等技術進步可能代表著市場機會。在全球範圍內，外包是尋求進入新市場的贊助商和製藥公司的解決方案。輝瑞和GlaxoSmithKline Plc等領先製藥公司已成功與當地 CMO 和 CRO 合作，幫助外國公司實現在新興國家的行銷、監管和製造目標。

此外，該行業不斷增加的合併和聯盟預計將在未來幾年擴大市場。例如，2023 年 1 月，分析解決方案公司 Bruker 收購了總部位於瑞士的臨床前 CRO Biogenesis，以擴大其臨床前能力。

CRO 市場的體內腫瘤學報告亮點

  • 固體癌市場佔比最大，達47.4%。這是因為癌症的發生率在世界各地不斷增加，世界衛生組織等全球組織對分析癌症發生率、致病因素和治療方法的興趣也越來越大，我們對此表示支持。
  • 在固體癌的模型中，患者來源的異質骨移植預計在預測期內的複合年成長率將達到 9.21%。
  • 2023年，北美地區將佔據全球最大佔有率，達到49.97%，美國將做出主要貢獻。這激發了研究活動的活力。大型製藥企業和生命科學公司已在該地區建立業務，並繼續推動市場成長。
  • 預計亞太地區在預測期內複合年成長率最快。這是由於許多新興國家在亞太地區進行投資以及受監管市場根據全球平台進行各種修訂來改變臨床試驗的評估標準。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章 CRO 體內腫瘤學市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • CRO 體內腫瘤學市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • COVID-19 影響分析
    • 主要交易及策略聯盟分析

第4章 CRO 體內腫瘤學市場：按適應症的估計和趨勢分析

  • CRO 體內腫瘤學市場，依適應症分類：細分儀表板
  • CRO 體內腫瘤學市場，依適應症分類：變異分析
  • 市場估計與預測：按指標分類，2018-2030 年

第5章 CRO 體內腫瘤學市場：區域估計與趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概述
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第6章 競爭狀況

  • 市場參與企業分類
    • 創新者
    • 市場領導者
    • 新興玩家
    • 2023 年企業市場佔有率分析
  • 公司簡介
    • Charles River Laboratory（CRL）
    • ICON Plc
    • Thermo Fisher Scientific Inc.
    • Eurofins Scientific
    • Taconic Biosciences
    • Crown Bioscience
    • Lab Corp
    • WuXi AppTec
    • EVOTEC
    • The Jackson Laboratory
Product Code: GVR-1-68038-859-6

Oncology Based In-vivo CRO Market Growth & Trends:

The global oncology based in-vivo CRO market size is expected to reach USD 2.37 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to grow at a CAGR of 8.58% over the forecast period. An increase in outsourcing of R&D activities, high demand for advanced medicines, and implementation of international standards by CROs are key factors driving the market growth.

Furthermore, the pressure from increasing competition due to patent expirations, the rapid growth of generics, and the introduction of biosimilar equivalents are propelling pharmaceutical companies to seek the aid of such organizations. Hence, it can be predicted that the oncology-based in-vivo CRO industry may witness lucrative growth over the forecast period.

Technological advancements such as mobile-enabled innovations for recruiting and communicating with participants, web-based life science labs and robotics labs to perform routine tests can be the opportunities of the market. At a global level, outsourcing is one of the solutions for sponsors and pharma companies seeking to make an entry into a new market. Big pharma companies such as Pfizer and GlaxoSmithKline partner with local CMOs and CROs, which have been successful in enabling foreign companies to achieve marketing, regulatory, and manufacturing goals in emerging economies.

Furthermore, an increase in the number of mergers and collaborations in this industry is expected to expand the market in the coming years. For instance, in January 2023, Bruker, an analytical solutions company, acquired a preclinical Switzerland-based CRO Biogenesis to expand its capabilities in preclinical activities.

Oncology Based In-vivo CRO Market Report Highlights:

  • The solid tumors segment held the largest share of 47.4% owing to the increasing incidence of cancer across the globe, and the growing interest of world agencies such as the WHO in analyzing their prevalence, causative agents, and treatment options is boosting R&D
  • Based on solid tumor-based model, patient-derived xenograft is anticipated to register the fastest CAGR of 9.21% over the forecast period
  • North America accounted for the largest global share of 49.97% in 2023, with the major contributions from the U.S., owing to increased funding available in the region. This has boosted research activities. Major pharmaceutical and life sciences companies continue to drive market growth with their established presence in the region
  • Asia Pacific is anticipated to register the fastest CAGR over the forecast period, owing to many developed countries investing in Asia Pacific regions and the various amendments made by the regulatory market to change the clinical trials evaluation standards according to the global platform

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
  • 1.3. Regional Scope
  • 1.4. Estimates And Forecast Timeline
  • 1.5. Objectives
    • 1.5.1. Objective-1
    • 1.5.2. Objective-2
    • 1.5.3. Objective-3
  • 1.6. Research Methodology
  • 1.7. Information Procurement
    • 1.7.1. Purchased Database
    • 1.7.2. GVR's Internal Database
    • 1.7.3. Secondary Sources
    • 1.7.4. Primary Research
  • 1.8. Information Or Data Analysis
    • 1.8.1. Data Analysis Models
  • 1.9. Market Formulation & Validation
  • 1.10. Model Details
    • 1.10.1. Commodity Flow Analysis
    • 1.10.2. Parent Market Analysis
  • 1.11. List Of Secondary Sources
  • 1.12. List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Oncology Based In-vivo CRO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Accelerating the time to market
      • 3.2.1.2. Economic efficiency
      • 3.2.1.3. Increasing mergers and collaborations
      • 3.2.1.4. Increasing outsourcing of R&D Activities
    • 3.2.2. Market Restraint Analysis
  • 3.3. Oncology Based In-vivo CRO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat Of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis
    • 3.3.4. Major Deals & Strategic Alliances Analysis

Chapter 4. Oncology Based In-vivo CRO Market: Indication Estimates & Trend Analysis

  • 4.1. Oncology Based In-vivo CRO Market, By Indication: Segment Dashboard
  • 4.2. Oncology Based In-vivo CRO Market, By Indication: Movement Analysis
  • 4.3. Oncology Based In-vivo CRO Market Estimates & Forecasts, By Indication, 2018 - 2030
    • 4.3.1. Blood cancer
      • 4.3.1.1. Blood Cancer Market, 2018 to 2030 (USD Million)
      • 4.3.1.2. Syngeneic model
      • 4.3.1.2.1. Syngeneic model Market, 2018 to 2030 (USD Million)
      • 4.3.1.3. Patient-derived xenograft
      • 4.3.1.3.1. Patient derived xenograft Market, 2018 to 2030 (USD Million)
      • 4.3.1.4. Xenograft
      • 4.3.1.4.1. Xenograft Market, 2018 to 2030 (USD Million)
    • 4.3.2. Solid tumor
      • 4.3.2.1. Solid Tumor Market, 2018 to 2030 (USD Million)
      • 4.3.2.2. Syngeneic model
      • 4.3.2.2.1. Syngeneic model Market, 2018 to 2030 (USD Million)
      • 4.3.2.3. Patient derived xenograft
      • 4.3.2.3.1. Patient derived xenograft Market, 2018 to 2030 (USD Million)
      • 4.3.2.4. Xenograft
      • 4.3.2.4.1. Xenograft Market, 2018 to 2030 (USD Million)
    • 4.3.3. Others
      • 4.3.3.1. Others Market, 2018 to 2030 (USD Million)
      • 4.3.3.2. Syngeneic model
      • 4.3.3.2.1. Syngeneic model Market, 2018 to 2030 (USD Million)
      • 4.3.3.3. Patient derived xenograft
      • 4.3.3.3.1. Patient derived xenograft Market, 2018 to 2030 (USD Million)
      • 4.3.3.4. Xenograft
      • 4.3.3.4.1. Xenograft Market, 2018 to 2030 (USD Million)

Chapter 5. Oncology Based In-vivo CRO Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Share Analysis, 2023 & 2030
  • 5.2. Regional Market Dashboard
  • 5.3. Global Regional Market Snapshot
  • 5.4. North America
    • 5.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. U.S.
      • 5.4.2.1. Key Country Dynamics
      • 5.4.2.2. Competitive Scenario
      • 5.4.2.3. Regulatory Scenario
      • 5.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 5.4.3. Canada
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Competitive Scenario
      • 5.4.3.3. Regulatory Scenario
      • 5.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
    • 5.4.4. Mexico
      • 5.4.4.1. Key Country Dynamics
      • 5.4.4.2. Competitive Scenario
      • 5.4.4.3. Regulatory Scenario
      • 5.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030
  • 5.5. Europe
    • 5.5.1. UK
      • 5.5.1.1. Key Country Dynamics
      • 5.5.1.2. Competitive Scenario
      • 5.5.1.3. Regulatory Scenario
      • 5.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 5.5.2. Germany
      • 5.5.2.1. Key Country Dynamics
      • 5.5.2.2. Competitive Scenario
      • 5.5.2.3. Regulatory Scenario
      • 5.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 5.5.3. France
      • 5.5.3.1. Key Country Dynamics
      • 5.5.3.2. Competitive Scenario
      • 5.5.3.3. Regulatory Scenario
      • 5.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 5.5.4. Italy
      • 5.5.4.1. Key Country Dynamics
      • 5.5.4.2. Competitive Scenario
      • 5.5.4.3. Regulatory Scenario
      • 5.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 5.5.5. Spain
      • 5.5.5.1. Key Country Dynamics
      • 5.5.5.2. Competitive Scenario
      • 5.5.5.3. Regulatory Scenario
      • 5.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 5.5.6. Denmark
      • 5.5.6.1. Key Country Dynamics
      • 5.5.6.2. Competitive Scenario
      • 5.5.6.3. Regulatory Scenario
      • 5.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 5.5.7. Sweden
      • 5.5.7.1. Key Country Dynamics
      • 5.5.7.2. Competitive Scenario
      • 5.5.7.3. Regulatory Scenario
      • 5.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 5.5.8. Norway
      • 5.5.8.1. Key Country Dynamics
      • 5.5.8.2. Competitive Scenario
      • 5.5.8.3. Regulatory Scenario
      • 5.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
  • 5.6. Asia Pacific
    • 5.6.1. Japan
      • 5.6.1.1. Key Country Dynamics
      • 5.6.1.2. Competitive Scenario
      • 5.6.1.3. Regulatory Scenario
      • 5.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 5.6.2. China
      • 5.6.2.1. Key Country Dynamics
      • 5.6.2.2. Competitive Scenario
      • 5.6.2.3. Regulatory Scenario
      • 5.6.2.4. China Market Estimates and Forecasts, 2018 - 2030
    • 5.6.3. India
      • 5.6.3.1. Key Country Dynamics
      • 5.6.3.2. Competitive Scenario
      • 5.6.3.3. Regulatory Scenario
      • 5.6.3.4. India Market Estimates and Forecasts, 2018 - 2030
    • 5.6.4. South Korea
      • 5.6.4.1. Key Country Dynamics
      • 5.6.4.2. Competitive Scenario
      • 5.6.4.3. Regulatory Scenario
      • 5.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 5.6.5. Australia
      • 5.6.5.1. Key Country Dynamics
      • 5.6.5.2. Competitive Scenario
      • 5.6.5.3. Regulatory Scenario
      • 5.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 5.6.6. Thailand
      • 5.6.6.1. Key Country Dynamics
      • 5.6.6.2. Competitive Scenario
      • 5.6.6.3. Regulatory Scenario
      • 5.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
  • 5.7. Latin America
    • 5.7.1. Brazil
      • 5.7.1.1. Key Country Dynamics
      • 5.7.1.2. Competitive Scenario
      • 5.7.1.3. Regulatory Scenario
      • 5.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 5.7.2. Argentina
      • 5.7.2.1. Key Country Dynamics
      • 5.7.2.2. Competitive Scenario
      • 5.7.2.3. Regulatory Scenario
      • 5.7.2.4. Argentina Market Estimates and Forecasts, 2018 - 2030
  • 5.8. MEA
    • 5.8.1. South Africa
      • 5.8.1.1. Key Country Dynamics
      • 5.8.1.2. Competitive Scenario
      • 5.8.1.3. Regulatory Scenario
      • 5.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 5.8.2. Saudi Arabia
      • 5.8.2.1. Key Country Dynamics
      • 5.8.2.2. Competitive Scenario
      • 5.8.2.3. Regulatory Scenario
      • 5.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 5.8.3. UAE
      • 5.8.3.1. Key Country Dynamics
      • 5.8.3.2. Competitive Scenario
      • 5.8.3.3. Regulatory Scenario
      • 5.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 5.8.4. Kuwait
      • 5.8.4.1. Key Country Dynamics
      • 5.8.4.2. Competitive Scenario
      • 5.8.4.3. Regulatory Scenario
      • 5.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 6. Competitive Landscape

  • 6.1. Market Participant Categorization
    • 6.1.1. Innovators
    • 6.1.2. Market Leaders
    • 6.1.3. Emerging Players
    • 6.1.4. Company Market Share Analysis, 2023
  • 6.2. Company Profiles
    • 6.2.1. Charles River Laboratory (CRL)
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Financial Performance
      • 6.2.1.3. Service Benchmarking
      • 6.2.1.4. Strategic Initiatives
    • 6.2.2. ICON Plc
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Financial Performance
      • 6.2.2.3. Service Benchmarking
      • 6.2.2.4. Strategic Initiatives
    • 6.2.3. Thermo Fisher Scientific Inc.
      • 6.2.3.1. Company Overview
      • 6.2.3.2. Financial Performance
      • 6.2.3.3. Service Benchmarking
      • 6.2.3.4. Strategic Initiatives
    • 6.2.4. Eurofins Scientific
      • 6.2.4.1. Company Overview
      • 6.2.4.2. Financial Performance
      • 6.2.4.3. Service Benchmarking
      • 6.2.4.4. Strategic Initiatives
    • 6.2.5. Taconic Biosciences
      • 6.2.5.1. Company Overview
      • 6.2.5.2. Financial Performance
      • 6.2.5.3. Service Benchmarking
      • 6.2.5.4. Strategic Initiatives
    • 6.2.6. Crown Bioscience
      • 6.2.6.1. Company Overview
      • 6.2.6.2. Financial Performance
      • 6.2.6.3. Service Benchmarking
      • 6.2.6.4. Strategic Initiatives
    • 6.2.7. Lab Corp
      • 6.2.7.1. Company Overview
      • 6.2.7.2. Financial Performance
      • 6.2.7.3. Service Benchmarking
      • 6.2.7.4. Strategic Initiatives
    • 6.2.8. WuXi AppTec
      • 6.2.8.1. Company Overview
      • 6.2.8.2. Financial Performance
      • 6.2.8.3. Service Benchmarking
      • 6.2.8.4. Strategic Initiatives
    • 6.2.9. EVOTEC
      • 6.2.9.1. Company Overview
      • 6.2.9.2. Financial Performance
      • 6.2.9.3. Service Benchmarking
      • 6.2.9.4. Strategic Initiatives
    • 6.2.10. The Jackson Laboratory
      • 6.2.10.1. Company Overview
      • 6.2.10.2. Financial Performance
      • 6.2.10.3. Service Benchmarking
      • 6.2.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 North America Oncology Based In-vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 4 North America Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 5 U.S. Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 6 Canada Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 7 Mexico Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 8 Europe Oncology Based In-vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 9 Europe Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 10 UK Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 11 Germany Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 12 France Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 13 Italy Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 14 Spain Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 15 Denmark Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 16 Sweden Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 17 Norway Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 18 Asia Pacific Oncology Based In-vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 19 Asia Pacific Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 20 Japan Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 21 China Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 22 India Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 23 South Korea Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 24 Australia Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 25 Thailand Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 26 Latin America Oncology Based In-vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 27 Latin America Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 28 Brazil Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 29 Argentina Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 30 Middle East & Africa Oncology Based In-vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 31 Middle East & Africa Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 32 South Africa Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 33 Saudi Arabia Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 34 UAE Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 35 Kuwait Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Oncology Based In-vivo CRO Market revenue, 2018 - 2030 (USD Million)
  • Fig. 10 Oncology Based In-vivo CRO Market snapshot
  • Fig. 11 Oncology Based In-vivo CRO Market driver impact
  • Fig. 12 Oncology Based In-vivo CRO Market restraint impact
  • Fig. 13 Oncology Based In-vivo CRO sector key takeaways (USD Million)
  • Fig. 14 Oncology Based In-vivo CRO Market: Type movement analysis
  • Fig. 15 Blood cancer market, 2018 - 2030 (USD Million)
  • Fig. 16 Syngeneic model market, 2018 - 2030 (USD Million)
  • Fig. 17 Patient derived xenograft market, 2018 - 2030 (USD Million)
  • Fig. 18 Xenograft market, 2018 - 2030 (USD Million)
  • Fig. 19 Solid tumor market, 2018 - 2030 (USD Million)
  • Fig. 20 Syngeneic model market, 2018 - 2030 (USD Million)
  • Fig. 21 Patient derived xenograft market, 2018 - 2030 (USD Million)
  • Fig. 22 Xenograft market, 2018 - 2030 (USD Million)
  • Fig. 23 Others market, 2018 - 2030 (USD Million)
  • Fig. 24 Syngeneic model market, 2018 - 2030 (USD Million)
  • Fig. 25 Patient derived xenograft market, 2018 - 2030 (USD Million)
  • Fig. 26 Xenograft market, 2018 - 2030 (USD Million)
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 Regional outlook, 2023 & 2030
  • Fig. 29 North America Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 31 Canada Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 33 Europe Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 34 UK Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 35 Germany Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 36 France Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 37 Italy Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 38 Spain Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 39 Denmark Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 41 Norway Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 42 Asia Pacific Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 43 Japan Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 44 China Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 45 India Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 46 South Korea Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 47 Australia Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 49 Latin America Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 50 Brazil Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 51 Argentina Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 52 Middle East & Africa Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 55 UAE Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 56 Kuwait Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 57 Market participant categorization